抗病毒三十六计——浅谈小分子抗病毒药物发展史

doi:10.12461/PKU.DXHX202403108

大学化学 >> 2024, Vol. 39 >> Issue (9): 85-93.doi: 10.12461/PKU.DXHX202403108

所属专题：化学科普(2024)

抗病毒三十六计——浅谈小分子抗病毒药物发展史

王哲祺^1,2, 林雅雯³, 邓顺柳^1,2, 张慧君^1,2, 周金梅^1,2

1 厦门大学化学化工学院, 福建厦门 361005;
2 厦门大学化学国家级实验教学示范中心, 福建厦门 361005;
3 厦门大学药学院, 福建厦门 361102

收稿日期:2024-03-29 修回日期:2024-05-23 发布日期:2024-09-23
通讯作者: 张慧君, 周金梅 E-mail:meghjzhang@xmu.edu.cn;jmzhou@xmu.edu.cn
基金资助:
2021年厦门大学教学改革研究项目(JG20210127)；2021年福建省本科高校教育教学改革研究项目(FBJG20210279)；基础学科拔尖学生培养计划2.0研究课题(20222108)

Antiviral Strategies: A Brief Review of the Development History of Small Molecule Antiviral Drugs

Zheqi Wang^1,2, Yawen Lin³, Shunliu Deng^1,2, Huijun Zhang^1,2, Jinmei Zhou^1,2

1 College of Chemistry and Chemical Engineering, Xiamen University, Xiamen 361005, Fujian Province, China;
2 National Demonstration Center for Experimental Chemistry Education, Xiamen University, Xiamen 361005, Fujian Province, China;
3 School of Pharmaceutical Science, Xiamen University, Xiamen 361102, Fujian Province, China

Received:2024-03-29 Revised:2024-05-23 Published:2024-09-23
Contact: Huijun Zhang, Jinmei Zhou E-mail:meghjzhang@xmu.edu.cn;jmzhou@xmu.edu.cn

摘要/Abstract

摘要： 病毒一直是人类生存和发展的重大威胁，近年来新冠肺炎疫情更是直观地凸显了病毒的危害性。小分子药物在人类抗击疾病的历史中扮演着重要的角色。在对抗病毒的过程中，人类发展出一系列防治手段，其中小分子抗病毒药物占据着重要地位。本文借鉴中国古代经典军事策略“三十六计”的智慧，简要回顾了小分子抗病毒药物的发展历程，并着重介绍了碘苷、沙奎那韦、奥司他韦等代表性药物的设计思路与作用原理。此外，本文还展望了小分子抗病毒药物及抗病毒手段未来的发展方向。

关键词: 抗病毒, 小分子药物, 三十六计

Abstract: Viruses have long been a significant threat to human survival and development, with recent events such as the COVID-19 pandemic vividly highlighting their dangers. Small molecule drugs have historically played a crucial role in humanity’s efforts to combat diseases. In the fight against viruses, humans have developed a range of strategies, with small molecule antiviral drugs occupying a pivotal position. Drawing inspiration from the classic “Thirty-Six Stratagems” of ancient Chinese military tactics, this article provides a concise overview of the developmental history of small molecule antiviral drugs, focusing on the design principles and mechanisms of representative drugs like idoxuridine, saquinavir, and oseltamivir. Furthermore, the article provides insights into future directions for small molecule antiviral drugs and antiviral methodologies.

Key words: Antivirus, Small molecule drugs, Thirty-Six stratagems

王哲祺, 林雅雯, 邓顺柳, 张慧君, 周金梅. 抗病毒三十六计——浅谈小分子抗病毒药物发展史[J]. 大学化学, 2024, 39(9): 85-93.

Zheqi Wang, Yawen Lin, Shunliu Deng, Huijun Zhang, Jinmei Zhou. Antiviral Strategies: A Brief Review of the Development History of Small Molecule Antiviral Drugs[J]. University Chemistry, 2024, 39(9): 85-93.

链接本文: https://www.dxhx.pku.edu.cn/CN/10.12461/PKU.DXHX202403108

https://www.dxhx.pku.edu.cn/CN/Y2024/V39/I9/85

参考文献

[1] 刘宁, 李文刚. 时珍国医国药, 2008, 18 (9), 2298.
[2] Voigt, E. A.; Kennedy, R. B.; Poland, G. A. Expert Rev. Vaccines 2016, 15, 1197.
[3] Baer, G. M. The Natural History of Rabies, 2nd ed.; Elsevier Science CA: New York, NY, USA, 2007; pp. 11–19.
[4] Isaacs, A.; Lindenmann, J. Proc. R. Soc. Lond. Ser. B 1957, 147, 258.
[5] Pestka, S. J. Biol. Chem. 2007, 282, 20047.
[6] Beck, H.; Härter, M.; Haß, B.; Schmeck, C.; Baerfacker, L. Drug Discov. Today 2022, 27, 1560.
[7] Clercq, E.; Li, G. Clin. Microbiol. Rev. 2016, 29, 695.
[8] Clercq, E. Nat. Rev. Microbiol. 2004, 2, 704.
[9] Ryu, W. S. Molecular Virology of Human Pathogenic Viruses; Elsevier: Amsterdam, the Netherlands, 2017; pp 31−45.
[10] Connolly, S.; Jackson, J.; Jardetzky, T.; Longnecker, R. Nat. Rev. Microbiol. 2011, 9, 369.
[11] 王萍, 饶红华, 林世静, 刘姗姗, 马磊. 化学教育(中英文), 2023, 44 (8), 1.
[12] Hitchings, G. H.; Elion, G. B.; Falco, E.; Russell, P. B.; Vanderwerff, H. Biol. Chem. 1950, 183, 1.
[13] Bieber, S.; Nigrelli, R. F.; Hitchings, G. H. Proc. Soc. Exp. Biol. Med. 1952, 79, 430.
[14] 孙彦莹, 康东伟, 高升华, 展鹏, 刘新泳. 中国药物化学杂志, 2021, 31 (1), 55.
[15] Prusoff, W. H. Biochim. Biophys. Acta 1959, 32, 295.
[16] Herrmann, E. C. Pro. Soc. Exp. Biol. Med. 1961, 107, 142.
[17] Kaufman, H. E.; Martola, E. L.; Dohlman, C. Arch. Ophthalmol. 1962, 68, 235.
[18] Wilhelmus, K. R. Cochrane Database Syst. Rev. 2010, 12, CD002898.
[19] Clercq, E. Clin. Microbiol. Rev. 1997, 10, 674.
[20] Clercq, E. Biochem. Pharmacol. 2004, 68, 2301.
[21] Andrei, G.; Sienaert, R.; McGuigan, C.; Clercq, E.; Balzarini, J.; Snoeck, R. Antimicrob. Agents Chemother. 2005, 49, 1081.
[22] Clercq, E.; Ashwell, M.; Jones, A. S.; Kumar, A.; Sayers, J. R.; Walker, R. T.; Sakuma, T. Tetrahedron 1987, 43, 4601.
[23] Asakura, J.; Robins, M. J. J. Org. Chem. 1990, 55, 4928.
[24] Glinski, R. P.; Khan, M. S.; Kalamas, R. L.; Sporn, M. B. J. Org. Chem. 1973, 38, 4299.
[25] Chu, C. K.; Beach, J. W.; Ullas, G. V.; Kosugi, Y. Tetrahedron Lett. 1988, 29, 5349.
[26] Fleet, G. W. J.; Son, J. C.; Derome, A. E. Tetrahedron 1988, 44, 625.
[27] Goodyear, M. D.; Hill, M. L.; West, J. P.; Whitehead, A. J. Tetrahedron Lett. 2005, 46, 8535.
[28] 王先登, 陈国华, 熊成文. 中国药物化学杂志, 2008, 18 (3), 203.
[29] Jin, H. L.; Siddiqui, M. A.; Evans, C. A.; Tse, H. L. A.; Mansour, T. S.; Goodyear, M. D.; Ravenscroft, P.; Beels, C. D. J. Org. Chem. 1995, 60, 2621.
[30] 孟静芳, 吴雪松, 岑均达. 中国医药工业杂志, 2005, 36 (10), 589.
[31] Freed, E. O. Virology 1998, 251, 1.
[32] Kramer, R. A.; Schaber, M. D.; Skalka, A. M.; Ganguly, K.; Wong, S. F.; Reddy, E. P. Science 1986, 231, 1580.
[33] Roberts, N. A.; Martin, J. A.; Kinchington, D.; Broadhurst, A. V.; Craig, J. C.; Duncan, I. B.; Galpin, S. A.; Handa, B. K.; Kay, J.; Machin, P. J.; et al. Science 1990, 248, 358.
[34] Kaldor, S. W.; Kalish, V. J.; Davies, J. F.; Shetty, B. V.; Fritz, J. E.; Appelt, K.; Burgess, J. A.; Campanale, K. M.; Chirgadze, N. Y.; Clawson, D. K.; et al. J. Med. Chem. 1997, 40, 3979.
[35] Inaba, T.; Birchler, A. G.; Yamada, Y.; Sagawa, S.; Yokota, K.; Ando, K.; Uchida, I. J. Org. Chem. 1998, 63, 7582.
[36] Parkes, K. E. B.; Bushnell, D. J.; Crackett, P. H.; Dunsdon, S. J.; Freeman, A. C.; Gunn, M. P.; Hopkins, R. A.; Lambert, R. W.; Martin, J. A.; Merrett, J. H.; et al. J. Org. Chem. 1994, 59, 3656.
[37] Corey, E. J.; Zhang, F. Y. Angew. Chem. Int. Ed. 1999, 38, 1931.
[38] Kim, B. M.; Bae, S. J.; So, S. M.; Yoo, H. T.; Chang, S. K.; Lee, J. H.; Kang, J. S. Org. Lett. 2001, 3, 2349.
[39] Ghosh, A. K.; Kincaid, J. F.; Walters, D. E.; Chen, Y.; Chaudhuri, N. C.; Thompson, W. J.; Culberson, C.; Fitzgerald, P. M. D.; Lee, H. Y.; McKee, S. P.; et al. J. Med. Chem. 1996, 39, 3278.
[40] Yu, R. H.; Polniaszek, R. P.; Becker, M. W.; Cook, C. M.; Yu. L. H. L. Org. Process Res. Dev. 2007, 11, 972.
[41] Canoy, W. L.; Cooley, B. E.; Corona, J. A.; Lovelace, T. C.; Millar, A.; Weber, A. M.; Xie, S. P.; Zhang, Y. Org. Lett. 2008, 10, 1103.
[42] Ghosh, A. K.; Shin, D.; Packiarajan, M. Chem. Commun. 1999, 1025.
[43] Benedetti, F.; Norbedo, S. Chem. Commun. 2001, 203.
[44] 曾祥兴, 李文刚. 时珍国医国药, 2008, 18 (9), 2298.
[45] 陈丹阳, 郑思钰, 郑锐林, 苏静瑶, 朱冰, 李英华. 检验医学, 2023, 38 (7), 696.
[46] Skehel, J. J.; Wiley, D. C. Annu. Rev. Biochem. 2000, 69, 531.
[47] Palese, P.; Jobita, K.; Ueda, M.; Compans, R. W. Virology 1974, 61, 397.
[48] Liu, C.; Eichelberger, M. C.; Compans, R. W.; Air, G. M. J. Virol. 1995, 69, 1099.
[49] Balakin, K. V.; Filosa, R.; Lavrenov, S. N.; Mkrtchyan, A. S.; Nawrozkij, M. B.; Novakov, I. A. Russ. Chem. Rev. 2018, 87, 509.
[50] Kadam, R. U.; Wilson, I. A. Proc. Natl. Acad. Sci. U.S.A. 2017, 114, 206.
[51] Air, G. M.; Laver, W. G.; Luo, M.; Stray, S. J.; Legrone, G.; Webster, R. G. Virology 1990, 177, 578.
[52] Blok, J.; Air, G. M.; Laver, W. G.; Ward, C. W.; Lilley, G. G.; Wood, E. F.; Roxburgh, C. M.; Inglis, A. S. Virology 1982, 119, 109.
[53] Colman, P. M. Pept. Protein Rev. 1984, 4, 215.
[54] Itzstein, M.; Wu, W. Y.; Kok, G. B.; Pegg, M. S.; Dyason, J. C.; Jin, B.; Phan, T. V.; Smythe, M. L.; White, H. F.; Oliver, S. W.; et al. Nature 1993, 363, 418.
[55] Chong, A. K. J.; Pegg, M. S.; Taylor, N. R.; von Itzstein, M. Eur. J. Biochem. 1992, 207, 335.
[56] Kim, C. U.; Lew, W.; Williams, M. A.; Liu, H. T.; Zhang, L. J.; Swaminathan, S.; Bischofberger, N.; Chen, M. S.; Mendel, D. B.; Tai, C. Y.; et al. J. Am. Chem. Soc. 1997, 119, 681.
[57] Rohloff, J. C.; Kent, K. M.; Postich, M. J.; Becker, M. W.; Chapman, H. H.; Kelly, D. E.; Lew, W.; Louie, M. S.; McGee, L. R.; Prisbe, E. J.; et al. J. Org. Chem.; 1998, 63, 4545.
[58] Federspiel, M.; Fischer, R.; Hennig, M.; Mair, H. J.; Oberhauser, T.; Rimmler, G.; Albiez, T.; Bruhin, J.; Estermann, H.; Gandert, C.; et al. Org. Process Res. Dev. 1999, 3, 266.
[59] 占弋丰, 张小林, 欧阳红霞. 化工中间体, 2012, 9 (5), 1.
[60] 张伟东, 崔恩惠, 徐露, 张凯育, 罗巧云. 化工设计通讯, 2019, 45 (11), 108.
[61] 张中朋. 中国现代中药, 2006, 8 (4), 41.
[62] Sagandira, C. R.; Mathe, F. M.; Guyo, U.; Watts, P. Tetrahedron 2020, 76, 131440.
[63] Hayashi, Y. J. Org. Chem. 2021, 86, 1.
[64] 曹瑞源, 赵磊, 钟武. 临床药物治疗杂志, 2018, 16 (1), 1.

抗病毒三十六计——浅谈小分子抗病毒药物发展史

Antiviral Strategies: A Brief Review of the Development History of Small Molecule Antiviral Drugs

PDF

赞

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 4

Metrics

推荐阅读 0

[1]	袁博, 冯辰昀, 袁耀锋. 治疗COVID-19的小分子药物研究进展[J]. 大学化学, 2023, 38(8): 85 -94 .
[2]	薛圣志, 毕金龙, 惠新平, 武全香. 上市小分子抗病毒药物研究进展[J]. 大学化学, 2023, 38(12): 91 -105 .
[3]	展鹏, 刘新泳. 研教融合型药学专业教学案例库的构建：以抗SARS-CoV-2药物研发为例[J]. 大学化学, 2023, 38(12): 10 -17 .
[4]	孙孝斌, 苗志伟. 磷酰胺酯前药策略及ProTide技术在抗病毒药物研发中的应用[J]. 大学化学, 2020, 35(12): 35 -43 .